Skip to content
OpenCapital
Get started

Ionis Pharmaceuticals IONS Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

ALN
Alnylam PharmaceuticalsALNY
——

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income?
Ionis Pharmaceuticals (IONS) reported increase (decrease) in contract liabilities and current deferred income of -$20.82M in Q1 2026.
How has Ionis Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income changed year-over-year?
Ionis Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income decreased by 51.8% year-over-year, from -$13.72M to -$20.82M.
What is the long-term trend for Ionis Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income?
Over 4 years (2021 to 2025), Ionis Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income has grown at a -4.2% compound annual growth rate (CAGR), from -$82.83M to -$69.73M.
What does increase (decrease) in contract liabilities and current deferred income mean?
The change in revenue received in advance for goods or services not yet delivered.
How do you interpret increase (decrease) in contract liabilities and current deferred income?
An increase indicates higher deferred revenue, signaling future revenue growth potential, while a decrease indicates the recognition of previously deferred revenue.
How does increase (decrease) in contract liabilities and current deferred income compare across companies?
Standard metric for software, biotech, and subscription-based businesses with multi-year contracts.